Spectrum Pharmaceuticals, Inc.
Head Quarters
Suite 240 11500 South Eastern Avenue USWebsite
http://www.sppirx.comIndustry
BiotechnologyEmployees
227Exchange
NASDAQSpectrum Pharmaceuticals, Inc. engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It targets non-Hodgkin's lymphoma, advanced metastatic colorectal cancer, acute lymphoblastic leukemia, and multiple myeloma. It operates through the following brands: FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, EVOMELA, EOQUIN, and RenaZorb. The company was founded in December 1987 and is headquartered in Henderson, NV.
Key statistics
| Margins | Stock |
|---|---|
| Revenue per Employee | $0.00 |
| Current Ratio | 3 |
| Gross Margin (%) | 0.50% |
| Net Margin (%) | -0.17% |
| Returns | Stock |
| Sales | $131.00M |
| Sales Growth (% qtr vs. yr ago) | 0.00% |
| Net Income | -$20.00M |
| NI Growth (% qtr vs. yr ago) | 0.00% |
| Price/Sales | 2.77 |
| EPS | -$1.00 |